Hui Huang1, Jing Li1, Wen-Jia Hu1, Chen Chen1, Hai-Qing Luo2, Xu-Dong Tang1,3,4, Ke-Yuan Zhou1,3,4, Wang-Tao Zhong5, Xiang-Yong Li1,3,4. 1. 1 Institute of Biochemistry and Molecular Biology, Guangdong Medical University, P.R. China. 2. 2 Center of Oncology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, P.R. China. 3. 3 Collaborative Innovation Center for Antitumor Active Substance Research and Development, Guangdong Medical University, P.R. China. 4. 4 Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, P.R. China. 5. 5 Department of Neurology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, P.R. China.
Abstract
BACKGROUND: CC chemokine ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers. Our previous research showed that the expression of CCL18 is obviously higher in non-small cell lung cancer (NSCLC) than in the adjacent normal tissues, suggesting its role in NSCLC. METHODS: We further examined the serum level of CCL18 in 80 NSCLC patients with enzyme-linked immunosorbent assay and simultaneously analyzed the survival curve of these patients by the Kaplan-Meier method, and then utilized a log-rank test to evaluate the correlation of CCL18 expression with the malignant progression of NSCLC. RESULTS: Our results showed that the median serum concentration of CCL18 was significantly elevated to 436.11 ng/mL in NSCLC patients compared to 41.97 ng/ml in healthy people (P<0.01), which was also positively related to the expression of lung cancer biomarkers carcinoma-embryonic antigen and cytokeratin fragment antigen 21-1. Moreover, correlation analysis showed that an increased level of serum CCL18 was associated with a worse survival time in NSCLC patients. CONCLUSION: Our findings suggest that the serum CCL18 level of NSCLC patients was negatively correlated with the prognosis, thus suggesting that CCL18 may serve as a potential circulating biomarker for NSCLC diagnosis.
BACKGROUND: CC chemokine ligand 18 (CCL18) is a chemotactic cytokine involved in the pathogenesis and progression of various cancers. Our previous research showed that the expression of CCL18 is obviously higher in non-small cell lung cancer (NSCLC) than in the adjacent normal tissues, suggesting its role in NSCLC. METHODS: We further examined the serum level of CCL18 in 80 NSCLC patients with enzyme-linked immunosorbent assay and simultaneously analyzed the survival curve of these patients by the Kaplan-Meier method, and then utilized a log-rank test to evaluate the correlation of CCL18 expression with the malignant progression of NSCLC. RESULTS: Our results showed that the median serum concentration of CCL18 was significantly elevated to 436.11 ng/mL in NSCLC patients compared to 41.97 ng/ml in healthy people (P<0.01), which was also positively related to the expression of lung cancer biomarkers carcinoma-embryonic antigen and cytokeratin fragment antigen 21-1. Moreover, correlation analysis showed that an increased level of serum CCL18 was associated with a worse survival time in NSCLC patients. CONCLUSION: Our findings suggest that the serum CCL18 level of NSCLC patients was negatively correlated with the prognosis, thus suggesting that CCL18 may serve as a potential circulating biomarker for NSCLC diagnosis.
Authors: Elena Cantero-Navarro; Sandra Rayego-Mateos; Macarena Orejudo; Lucía Tejedor-Santamaria; Antonio Tejera-Muñoz; Ana Belén Sanz; Laura Marquez-Exposito; Vanessa Marchant; Laura Santos-Sanchez; Jesús Egido; Alberto Ortiz; Teresa Bellon; Raúl R Rodrigues-Diez; Marta Ruiz-Ortega Journal: Front Med (Lausanne) Date: 2021-07-08
Authors: Sowmya Ramachandran; Amit K Verma; Kapil Dev; Yamini Goyal; Deepti Bhatt; Mohammed A Alsahli; Arshad Husain Rahmani; Ahmad Almatroudi; Saleh A Almatroodi; Faris Alrumaihi; Naushad Ahmad Khan Journal: Oxid Med Cell Longev Date: 2021-07-16 Impact factor: 6.543